Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroferritinopathy.

John Burn1, Patrick F Chinnery

  • 1Institute of Human Genetics, Newcastle University, Newcastle on Tyne, UK. John.burn@newcastle.ac.uk

Seminars in Pediatric Neurology
|November 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Slc5a6-Deficient Mouse Model Reveals Metabolically Driven Cardiomyopathy with Therapeutic Potential for Vitamin-Based Intervention.

JCI insight·2026
Same author

Platelet activation, aspirin, and cancer: From basic science to clinical trials.

Pharmacological reviews·2026
Same author

Understanding How Aspirin Prevents Metastasis.

The New England journal of medicine·2025
Same author

Detection of urothelial carcinoma in Lynch syndrome using microsatellite instability analysis of urine cell-free DNA.

EBioMedicine·2025
Same author

Optimizing risk-reducing surgery and aspirin decision aids for Lynch syndrome carriers using the person-based approach: A think-aloud interview study.

Journal of genetic counseling·2025
Same author

Suspending the NHS medicines repurposing programme in England is a missed opportunity.

BMJ (Clinical research ed.)·2025
Same journal

Concussion in contact sport: risks, detection, & prevention.

Seminars in pediatric neurology·2026
Same journal

A multidisciplinary, symptom-targeted approach to rehabilitation in pediatric concussion.

Seminars in pediatric neurology·2026
Same journal

Pediatric concussion beyond sports: Falls, play, and everyday activities.

Seminars in pediatric neurology·2026
Same journal

Return-to-school protocols in pediatric concussion care.

Seminars in pediatric neurology·2026
Same journal

Improving concussion recognition in youth sports: the role of parents, coaches, and community education.

Seminars in pediatric neurology·2026
Same journal

Concussion management, rehabilitation, and societal impact.

Seminars in pediatric neurology·2026
See all related articles

Neuroferritinopathy is a progressive movement disorder caused by mutations in the ferritin light chain gene (FTL1). This condition leads to iron accumulation in neurons, causing neurological symptoms and offering new therapeutic targets for iron storage disorders.

Area of Science:

  • Genetics
  • Neuroscience
  • Biochemistry

Background:

  • Neuroferritinopathy, also known as hereditary ferritinopathy or NBIA2, is an adult-onset progressive movement disorder.
  • It is caused by mutations in the ferritin light chain gene (FTL1).
  • Four pathogenic mutations in FTL1 have been identified, including a founder mutation (460insA) in Cumbria, England, and a separate occurrence in France.

Purpose of the Study:

  • To describe the genetic basis and clinical presentation of neuroferritinopathy.
  • To elucidate the mechanism of neurodegeneration linked to iron accumulation.
  • To explore potential therapeutic strategies targeting brain iron stores.

Main Methods:

  • Genetic analysis of patients with neuroferritinopathy.
  • Description of clinical neurological symptoms and their prevalence.

Related Experiment Videos

  • Pathological examination of affected neurons to assess ferritin and iron accumulation.

    • Main Results:

    • Mutations in FTL1 alter the ferritin structure, leading to iron and ferritin accumulation in central neurons.
    • Clinical manifestations include chorea (50%), limb dystonia (43%), and Parkinsonian features (7%).
    • The disorder establishes a direct link between aberrant iron storage and neurodegeneration.

    Conclusions:

    • Neuroferritinopathy provides a direct link between disordered iron storage and neurodegenerative disease.
    • Understanding this link opens new therapeutic avenues by targeting brain iron levels.
    • Symptomatic treatments like Botulinum toxin and antioxidants may complement iron-focused therapies.